(Total Views: 325)
Posted On: 09/15/2019 6:15:55 AM
Post# of 149994
Nice find!
With ours being reasonably priced, non-toxic and should prove superior, an NCCN recommendation would be justified.
Quote:
Our findings raise concern that the NCCN justifies the coverage of costly, toxic cancer drugs based on weak evidence.
With ours being reasonably priced, non-toxic and should prove superior, an NCCN recommendation would be justified.
(2)
(0)Scroll down for more posts ▼
